Source: FierceBiotech]
The 2007 edition of the European Commission's annual scoreboard of companies' spending on research and development (R&D) shows that corporate R&D has increased by 10%, with EU-based companies increasing their R&D investment by 7.4%. This compares to 5.3% growth reported in the 2006 edition. The scoreboard also shows an upward trend in companies' profitability all over the world. The world's biggest investor in R&D in the 2007 Scoreboard is Pfizer of the US, with €5.8 billion. The top EU company is DaimlerChrysler of Germany with €5.2 billion
"We are only ever going to improve our R&D performance if more companies see the benefit of investing in research," said European Science and Research Commissioner Janez Potočnik. "The positive upward trend in R&D investment seen in the last two years is encouraging, and leads me to believe that our innovation strategy is on the right track. But we must not allow ourselves to be complacent – quite the opposite: we should reinforce the positive measures already taken to consolidate and improve private investment in R&D."
The EU Industrial R&D Investment Scoreboard is published annually by the European Commission as part of its Industrial Research Investment Monitoring activity. The figures are derived from company accounts for the previous financial year and indicate the investment made by a company from its own funds. The Scoreboard does not reflect where the expenditure was made, just the origin of the company making the investment. The Scoreboard comprises the top1000 R&D companies from the EU and the top1000 R&D companies from the rest of the world. Together, the 2000 Scoreboard companies invested €372 billion in R&D, estimated to represent more than 85% of corporate expenditure on R&D worldwide.
On the downside, the report shows that R&D investment by EU companies is still growing at a lower rate than their non-EU counterparts, a trend identified in every edition of the Industrial R&D Scoreboard published to date. This difference is primarily explained by a growth rate in high R&D-intensive sectors outside the EU of almost twice that within the EU. These sectors also account for a much larger proportion of R&D outside the EU. Nevertheless, the EU did record the highest growth in fixed capital investment. This represents an important part of total corporate investment that also underpins investment in innovation.
In the coming months the European Commission will publish the 2006 EU Survey on R&D Investment Business Trends with information about 110 R&D EU companies' investment expectations for the period 2007-2009. This survey provides new insights into company expectations about future R&D investments and their motivations to invest in research. The preliminary results confirm the positive trends of the 2007 Scoreboard.
Sector trends
Pharmaceuticals & biotechnology becomes the top R&D investing sector, overtaking the technology hardware & equipment sector. This sector is represented by many EU companies. Many pharmaceutical companies show a strong increase of R&D investment, e.g. Merck (+24.3%), AztraZeneca (+15.5%), Roche (+15.5%), Johnson & Johnson (+12.9%), GlaxoSmithKline (+10%).
Chemicals shows a strong recovery in R&D investment (+9.8%), compared to the negative growth of the previous year. This is especially pronounced in the EU group of companies (+17%) where the large chemical companies show impressive R&D growth rates, e.g. Bayer (+30.3%), Solvay (+20.3%) and BASF (+19.8%). This is partly due to processes of acquisitions and concentration in the sector.
Aerospace and defence raised its R&D investment by 12.5% continuing the trend of strong growth of the past years. The sector's most representative companies, EADS and Boeing increased their R&D investment by 21.2% and 47.7% respectively.
Company trends
Three EU companies keep a position within the top 10 R&D ranking: DaimlerChrysler, the top EU company with 5.2 bn EUR (5th), GlaxoSmithKline (7th) and Siemens (8th). Four US companies are in the top positions: Pfizer (5.8 bn EUR), Ford Motor, Johnson & Johnson and Microsoft.
The performance of Scoreboard companies further improved in the past year. Sales of EU companies grew by 10% and sales of US and Japanese companies grew by about 8%. The profitability of EU companies increased further to 11.6% (between 12.9% for the US and 7.4% for Japan).
"We are only ever going to improve our R&D performance if more companies see the benefit of investing in research," said European Science and Research Commissioner Janez Potočnik. "The positive upward trend in R&D investment seen in the last two years is encouraging, and leads me to believe that our innovation strategy is on the right track. But we must not allow ourselves to be complacent – quite the opposite: we should reinforce the positive measures already taken to consolidate and improve private investment in R&D."
The EU Industrial R&D Investment Scoreboard is published annually by the European Commission as part of its Industrial Research Investment Monitoring activity. The figures are derived from company accounts for the previous financial year and indicate the investment made by a company from its own funds. The Scoreboard does not reflect where the expenditure was made, just the origin of the company making the investment. The Scoreboard comprises the top1000 R&D companies from the EU and the top1000 R&D companies from the rest of the world. Together, the 2000 Scoreboard companies invested €372 billion in R&D, estimated to represent more than 85% of corporate expenditure on R&D worldwide.
On the downside, the report shows that R&D investment by EU companies is still growing at a lower rate than their non-EU counterparts, a trend identified in every edition of the Industrial R&D Scoreboard published to date. This difference is primarily explained by a growth rate in high R&D-intensive sectors outside the EU of almost twice that within the EU. These sectors also account for a much larger proportion of R&D outside the EU. Nevertheless, the EU did record the highest growth in fixed capital investment. This represents an important part of total corporate investment that also underpins investment in innovation.
In the coming months the European Commission will publish the 2006 EU Survey on R&D Investment Business Trends with information about 110 R&D EU companies' investment expectations for the period 2007-2009. This survey provides new insights into company expectations about future R&D investments and their motivations to invest in research. The preliminary results confirm the positive trends of the 2007 Scoreboard.
Sector trends
Pharmaceuticals & biotechnology becomes the top R&D investing sector, overtaking the technology hardware & equipment sector. This sector is represented by many EU companies. Many pharmaceutical companies show a strong increase of R&D investment, e.g. Merck (+24.3%), AztraZeneca (+15.5%), Roche (+15.5%), Johnson & Johnson (+12.9%), GlaxoSmithKline (+10%).
Chemicals shows a strong recovery in R&D investment (+9.8%), compared to the negative growth of the previous year. This is especially pronounced in the EU group of companies (+17%) where the large chemical companies show impressive R&D growth rates, e.g. Bayer (+30.3%), Solvay (+20.3%) and BASF (+19.8%). This is partly due to processes of acquisitions and concentration in the sector.
Aerospace and defence raised its R&D investment by 12.5% continuing the trend of strong growth of the past years. The sector's most representative companies, EADS and Boeing increased their R&D investment by 21.2% and 47.7% respectively.
Company trends
Three EU companies keep a position within the top 10 R&D ranking: DaimlerChrysler, the top EU company with 5.2 bn EUR (5th), GlaxoSmithKline (7th) and Siemens (8th). Four US companies are in the top positions: Pfizer (5.8 bn EUR), Ford Motor, Johnson & Johnson and Microsoft.
The performance of Scoreboard companies further improved in the past year. Sales of EU companies grew by 10% and sales of US and Japanese companies grew by about 8%. The profitability of EU companies increased further to 11.6% (between 12.9% for the US and 7.4% for Japan).
Sanofi-Aventis
the U.K based pharmaceutical, was rated #5 in overall sales and 4th on the list of top R&D spenders in 2006. Sanofi has has trouble over the last year with its drug Acomplia failing to get U.S. Food and Drug Administration approval and its Alzheimer's drug, Xaliproden, failing in late-stage trials but it has several vaccines lined up and of the 48 drugs in late-stage trials, it expects to file for approval on 31 of them by the end of 2010.
Phase III
Rimonabant (Acomplia) - Type 2 diabetesNV1FGF (fibroblast growth factor) - Critical limb ischemiaEplivanserin, Volinanserin (5-HT2A antagonists) - sleep maintenance.Saredutant - Major depressive disorders and general anxiety disordersAmibegron - Major depressive disorders and general anxiety disordersAflibercept (VEGF Trap): Advanced ovarian cancer, prostate cancer, non-small cell lung cancerS-1 - Second-line treatment for pancreatic cancerMenactra Toddler - Meningococcal meningitisLow-dose H5N1 flu vaccine with adjuvantDianicline - Smoking cessationIlepatril - Blood pressure reduction and long-term cardiovascular and renal protection
Phase III
Rimonabant (Acomplia) - Type 2 diabetesNV1FGF (fibroblast growth factor) - Critical limb ischemiaEplivanserin, Volinanserin (5-HT2A antagonists) - sleep maintenance.Saredutant - Major depressive disorders and general anxiety disordersAmibegron - Major depressive disorders and general anxiety disordersAflibercept (VEGF Trap): Advanced ovarian cancer, prostate cancer, non-small cell lung cancerS-1 - Second-line treatment for pancreatic cancerMenactra Toddler - Meningococcal meningitisLow-dose H5N1 flu vaccine with adjuvantDianicline - Smoking cessationIlepatril - Blood pressure reduction and long-term cardiovascular and renal protection
Glaxosmithkline
ranked #3 in sales, invested 10% more in 2006 into research and development. The company experienced a huge hit when the FDA increased the warning label strength on the blockbuster drug Avandia. Add in the fact that several big drugs are nearing the end of their patent life and are facing generic competition and over all it wasn't a great year for GSK. However, the future looks bright for the company. The company has 33 drugs in Phase III development and expects to launch approximately 25 new drugs in the next two years.
Pending Approval:
Avandia + simvastatin - Type 2 diabetesHycamtin - small cell lung cancer, second-line therapy (oral formulationGloborix - diptheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b disease, Neisseria meningitis groups A & C disease prophylaxisInfanrix-IPV/Kinrix - Diptheria, tetanus, pertussis and poliomyelitis prophylaxisFlu pre-pandemic H5N1 - Pandemic influenza prophylaxisEntereg/Entrareg - Post operative ileus ApprovableGepirone ER - major depressive disorder, once-dailyLamictal XR - EpilepsyReQuip XR - Restless legs syndromeTrexima - Migraine
Phase III Pipeline:
Coreg CR† + ACE - hypertensionAvandamet XR - Type 2 diabetes Avandia - Type 2 diabetes, Prevention of diabetesDacart - Uncomplicated malariaHycamtin - Ovarian cancer, first-line therapyOfatumumab - Chronic lymphocytic leukaemia (also rheumatoid arthritis), follicular lymphomaPazopanib - Renal cell cancerPromacta/Revolade - Long-term idiopathic thrombocytopaenic purpura, short-term idiopathic thrombocytopaenic purpuraRezonic/Zunrisa - chemotherapy-induced & postoperative nausea & vomiting (also depression & anxiety)Tykerb/Tyverb ErbB-2 and EGFR - breast cancer, breast cancer brain metastases, breast cancer (first-line therapy), head & neck squamous cell carcinomasHib-MenCY-TT - Neisseria meningitis groups C & Y disease & Haemophilus influenzae type b disease prophylaxisMenACWY-TT - Neisseria meningitis groups A, C, W and Y disease prophylaxisSynflorix - Streptococcus pneumoniae & non-typable Haemophilus influenzae disease prophylaxis for childrenMAGE-A3 - Non-small cell lung cancerAvodart - Reduction in the risk of prostate cancerAvodart + alpha blocker - benign prostatic hyperplasiaBelimumab - Systemic lupus erythematosusBosatria - Hypereosinophilic syndrome (also severe asthma & nasal polyposis)Entereg/Entrareg - Opioid-induced bowel dysfunction1838262 - Restless legs syndromeLamictal XR - Partial generalised tonic-clonic seizures, once-dailyRosiglitazone XR - Alzheimer's disease
Pending Approval:
Avandia + simvastatin - Type 2 diabetesHycamtin - small cell lung cancer, second-line therapy (oral formulationGloborix - diptheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b disease, Neisseria meningitis groups A & C disease prophylaxisInfanrix-IPV/Kinrix - Diptheria, tetanus, pertussis and poliomyelitis prophylaxisFlu pre-pandemic H5N1 - Pandemic influenza prophylaxisEntereg/Entrareg - Post operative ileus ApprovableGepirone ER - major depressive disorder, once-dailyLamictal XR - EpilepsyReQuip XR - Restless legs syndromeTrexima - Migraine
Phase III Pipeline:
Coreg CR† + ACE - hypertensionAvandamet XR - Type 2 diabetes Avandia - Type 2 diabetes, Prevention of diabetesDacart - Uncomplicated malariaHycamtin - Ovarian cancer, first-line therapyOfatumumab - Chronic lymphocytic leukaemia (also rheumatoid arthritis), follicular lymphomaPazopanib - Renal cell cancerPromacta/Revolade - Long-term idiopathic thrombocytopaenic purpura, short-term idiopathic thrombocytopaenic purpuraRezonic/Zunrisa - chemotherapy-induced & postoperative nausea & vomiting (also depression & anxiety)Tykerb/Tyverb ErbB-2 and EGFR - breast cancer, breast cancer brain metastases, breast cancer (first-line therapy), head & neck squamous cell carcinomasHib-MenCY-TT - Neisseria meningitis groups C & Y disease & Haemophilus influenzae type b disease prophylaxisMenACWY-TT - Neisseria meningitis groups A, C, W and Y disease prophylaxisSynflorix - Streptococcus pneumoniae & non-typable Haemophilus influenzae disease prophylaxis for childrenMAGE-A3 - Non-small cell lung cancerAvodart - Reduction in the risk of prostate cancerAvodart + alpha blocker - benign prostatic hyperplasiaBelimumab - Systemic lupus erythematosusBosatria - Hypereosinophilic syndrome (also severe asthma & nasal polyposis)Entereg/Entrareg - Opioid-induced bowel dysfunction1838262 - Restless legs syndromeLamictal XR - Partial generalised tonic-clonic seizures, once-dailyRosiglitazone XR - Alzheimer's disease
Johnson & Johnson
U.S. based Johnson & Johnson found itself in the top 5 R&D spenders among pharmaceuticals with a 15.5% increase over the previous year's spending which translates into $5.4 bn Eur. Ranked #1 in sales, Johnson & Johnson expect 21 new drug filings or approvals over the next 3 years; five of which are expected by the end of this year.
Pending Approval:
Concerta - Adult ADHD Remicade - Pediatric Ulcerative Colitis, UC colectomy avoidanceCeftobiprole - Complicated Skin and Skin Structure InfectionsDoribax - Nosocomial PneumoniaTMC125 - NNRTI HIV/AIDS treatment-experienced patients
Phase III:
Invega (paliperidone ER OROS) - Bipolar maniaPaliperidone palmitate IM long acting injectable - SchizophreniaRisperdal Consta - Bipolar maintenance, Deltoid injectionCarisbamate - EpilepsyTopomax - Pediatric exclusivityCNTO 1275 (ustekinumab) - PsoriasisCNTO 148 (golimumab) - Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis Rheumatoid ArthritisProcrit - Chronic Renal FunctionCeftobiprole - Nosocomial Pneumonia, Hospitalized community acquired pneumoniaDoxil - Breast CancerVelcade - Non-Hodgkin's Lymphoma, Multiple Myeloma 1st lineYondelis - Relapsed Ovarian CancerDacogen - Injection Myelodysplastic SyndromesPrezista - Naïve & early experienced patientsTapentadol - Moderate to severe acute pain (IR formulation), moderate to severe chronic pain (ER formulation)Rivaroxaban VTE Prophylaxis, knee replacement surgery, stroke prevention in atrial fibrillation, VTE treatment
Pending Approval:
Concerta - Adult ADHD Remicade - Pediatric Ulcerative Colitis, UC colectomy avoidanceCeftobiprole - Complicated Skin and Skin Structure InfectionsDoribax - Nosocomial PneumoniaTMC125 - NNRTI HIV/AIDS treatment-experienced patients
Phase III:
Invega (paliperidone ER OROS) - Bipolar maniaPaliperidone palmitate IM long acting injectable - SchizophreniaRisperdal Consta - Bipolar maintenance, Deltoid injectionCarisbamate - EpilepsyTopomax - Pediatric exclusivityCNTO 1275 (ustekinumab) - PsoriasisCNTO 148 (golimumab) - Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis Rheumatoid ArthritisProcrit - Chronic Renal FunctionCeftobiprole - Nosocomial Pneumonia, Hospitalized community acquired pneumoniaDoxil - Breast CancerVelcade - Non-Hodgkin's Lymphoma, Multiple Myeloma 1st lineYondelis - Relapsed Ovarian CancerDacogen - Injection Myelodysplastic SyndromesPrezista - Naïve & early experienced patientsTapentadol - Moderate to severe acute pain (IR formulation), moderate to severe chronic pain (ER formulation)Rivaroxaban VTE Prophylaxis, knee replacement surgery, stroke prevention in atrial fibrillation, VTE treatment
Pfizer
The U.S based company, Pfizer Inc. (NYSE: PFE) which is ranked #2 in sales, invested $5.8 bn EUR in 2006 into research and development. In 2007 the company made the major decision to invest in biotech drugs which are less susceptible to generic competition. It reorganized its R&D operations by hiring Martin Mackay as its new chief of global R&D and announced the launch of a biotherapeutic and bioinnovation center to focus on securing new technologies and discovering new medicines. In December Pfizer announced that it was closing its Ann Arbor research facility and laying off 2,100 employees due to the fact that Lipitor is nearing the end of its patent life.
During a recent update Pfizer announced that it has 47 Phase II drugs, 11 Phase III drugs and 14 biologics in its pipeline.
Drugs Pending Approval:
Lasofoxifene - OsteoporosisMaraviroc - HIV in Treatment Experienced Patients Dalbavancin - Skin and Skin Structure Infections
Phase III:
CP-945598 - Obesity Apixaban - Venous Thromboembolism prevention, Atrial Fibrillation Zithromax/Chloroquine - Malaria CP-675206 - Melanoma Axitinib - Thyroid Cancer/Pancreatic Cancer Sutent - Breast Cancer, Colorectal Cancer, Lung Cancer Maraviroc - HIV in Treatment Naïve Patients Lyrica - Epilepsy Monotherapy, Generalized Anxiety Disorder (U.S.) Geodon - Bipolar Relapse Prevention
During a recent update Pfizer announced that it has 47 Phase II drugs, 11 Phase III drugs and 14 biologics in its pipeline.
Drugs Pending Approval:
Lasofoxifene - OsteoporosisMaraviroc - HIV in Treatment Experienced Patients Dalbavancin - Skin and Skin Structure Infections
Phase III:
CP-945598 - Obesity Apixaban - Venous Thromboembolism prevention, Atrial Fibrillation Zithromax/Chloroquine - Malaria CP-675206 - Melanoma Axitinib - Thyroid Cancer/Pancreatic Cancer Sutent - Breast Cancer, Colorectal Cancer, Lung Cancer Maraviroc - HIV in Treatment Naïve Patients Lyrica - Epilepsy Monotherapy, Generalized Anxiety Disorder (U.S.) Geodon - Bipolar Relapse Prevention
No comments:
Post a Comment